17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Swedish firm InDex Pharmaceuticals has announced that its board of directors has named Jenny Sundqvist as the company's new chief executive. 10 October 2022
In what could be a paradigm shift in the treatment of congestion due to worsening heart failure, the US Food and Drug Administration (FDA) has approved Furoscix (furosemide injection). 10 October 2022
Privately-held Covis Pharma knows what it is up against from the US Food and Drug Administration (FDA) as the regulator attempts to have the company’s preterm birth (PTB) drug Makena (hydroxyprogesterone caproate) withdrawn from the market. 10 October 2022
UK clinical stage drug development company Evgen Pharma saw its shares rocket more than 66% to 4.63 pence this morning, after it revealed the signing of global license for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. 10 October 2022
Commenting on a much-anticipated meeting of representatives of the Greek pharmaceutical sector with the Ministry of Health, the national trade group, the Hellenic Association of Pharmaceutical Companies (SFEE), concluded that it was fruitless. 10 October 2022
Competition for Novo Nordisk’s recently-approved weight loss drug Wegovy (semaglutide) is coming quickly, with Eli Lilly securing Fast Track designation for its rival therapy. 7 October 2022
On Friday, the US Food and Drug Administration approved Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed [Tdap]) for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. 7 October 2022
LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), today announced the appointments of Martin Stahl, as chief scientific officer and Louis Plamondon, as executive vice president and head of CMC. 6 October 2022
The share of counterfeit medicines in the Russian pharmaceutical market has declined to minimal figures in the last five years, which was mainly due to efforts that have been made by the state, according to a recent report published by the Russian pharmaceutical regulator Roszdravnadzor and some local media, reports The Pharma Letter’s local correspondent. 6 October 2022
The Russian government plans to speed up the development and production of domestic drugs against rare diseases amid the ever tightening pressure caused by sanctions on the country due to its military conflict with Ukraine. 6 October 2022
Glenmark Pharmaceuticals’ shares rose 1.2% to 408.75 rupees today, after the Indian drugmaker announced that it became the first company in India to launch thiazolidinedione lobeglitazone for the treatment of type 2 diabetes in adults. 6 October 2022
Market authorization was granted to 92 new medicines in the European Union (EU) last year.Market authorization was granted to 92 new medicines in the European Union (EU) last year. 5 October 2022
Victor Grifols Roura, who has devoted 50 years to building Spanish plasma-derived drugmaker Grifols (MCE: GRF) in senior roles including chief executive for 30 years, retires as non-executive chairperson. He is designated as chairperson of honor in recognition of his numerous contributions. 5 October 2022
Allecra Therapeutics, a France-based biopharmaceutical company dedicated to the development of novel antibiotics, today revealed that the prestigious Journal of the American Medical Association (JAMA) has published the final results from its Phase III ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections (cUTIs). 5 October 2022
Japan’s largest drugmaker Takeda says that it will discontinue manufacturing its injectable parathyroid hormone Natpar/Natpara globally at the end of 2024 due to unresolved supply issues that are specific to the product. 5 October 2022
Melatonin, a natural hormone that is produced by the pineal gland and used by many long-haul airline travellers to mitigate their jet-lag symptoms, has gained its first approval in the UK, but as a treatment for sleep onset insomnia in children and adolescents aged six-17 years with attention-deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been inadequate. 4 October 2022
Japanese pharma major Shionogi gained 1% to 7,035 yen today, after it announced a voluntary license agreement for its oral COVID-19 antiviral candidate ensitrelvir fumaric acid (S-217622) with the United Nations-backed Medicines Patent Pool (MPP), which aims to increase access to life-saving medicines for low- and middle-income countries (LMICs). 4 October 2022
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.